Twitter Chat Recap: What developments, treatments or medications are on the horizon that are most exciting for heart failure patients?



Question 7: What developments, treatments or medications are on the horizon that are most exciting for heart failure patients?


Heart Failure Society of America @HFSA

  • There appears to be promise w/ some newer medications either currently in clinical trials and/or going through the FDA approval process. SGLT2i therapy is a medication that was originally intended as a diabetes med. and more recently has been adopted into the HF world. #HFChat2022
  • Another diabetes med., GLP-1 agonist, is currently in clinical trials w/ some of our HF population. Patients diagnosed w/ obstructive hypertrophic cardiomyopathy have a possible new med. on the horizon called mavacamten, though this has not yet been approved. #HFChat2022 
  • Surgical techniques are always advancing in the heart transplant and LVAD world, as well. HFSA supports clinical trials and research through its Heart Failure Research Network. #HFChat2022 #HFWeek2022

American Association of Heart Failure Nurses @AAHFN

  • The ever-evolving transcatheter valve world is exciting! New advances in transcatheter mitral valve technologies shows promise in treating heart failure due to diseased mitral valves. These therapies have come a long way in a short amount of time. #HFChat2022 #HFWeek2022

The Heart Brothers Foundation @HeartBrothers1

  • More drugs coming from co's like @Novartis, @Cytokinetics & @Pfizer. New devices like the #impella. Smarter defibrillators from @AbbottCardio. More hearts avail from @TransMedics #OCS. Better post-transplant surveillance for longer life from co's like @CareDx. #HFChat2022
  • The list continues... Advancements in #DCD #hearttransplantation, use of #highriskhearts, use of modified pig hearts, stem cell therapy, and so so much more. #HFChat2022 #heartfailureawareness #lifeaftertransplant #hearttransplantsurvivors

Hypertrophic Cardiomyopathy Association @4hcm

  • HCM is finally getting the attention it deserved with new medications under investigation and 1 under FDA review, Mavacamten. We await word from the FDA for a potential new tool in the tool box of HCM management!  #HFChat2022
  • Those at high risk for cardiac arrest can be protected with an implantable defibrillator.… #HFchat2022

International Society for Heart and Lung Transplantation @ISHLT

  • There are a wide variety of novel therapeutics that not only conserve a reduced functional status, but can regain strength and function to allow a more normal life. Clinicians can learn more about the latest #HF science at #ISHLT2022 this April:

Mended Hearts @MendedHearts

  • As a patient organization we are excited to learn what’s on the horizon. It’s exciting that so much research is focusing on HF and bringing the patient voice to the table. #HFChat2022